ONCO
Onconetix, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.02
+38.02%Year over year
Reported trailing growth
- Revenue
- -51.3%
- EBITDA
- +77.4%
- EBIT
- +76.5%
- EPS
- +98.3%
- Free cash flow
- -88.1%
- Operating cash flow
- -88.3%
Forward estimates
Based on analyst estimates
- Revenue
- -88.9%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +273.4%
- EBITDA
- +77.0%
- EBIT
- +88.8%
- Net income
- +76.1%
- EPS
- +99.1%
- Free cash flow
- +8.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026